Patents by Inventor Alexander Sulakvelidze
Alexander Sulakvelidze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124851Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of pathogenic E. coli, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of pathogenic E. coli in various settings (e.g., food safety, environmental—including food establishments and medical settings—sanitation, urinary tract infections, modulating microbiome, prebiotics, probiotics).Type: ApplicationFiled: September 21, 2023Publication date: April 18, 2024Inventor: Alexander SULAKVELIDZE
-
Publication number: 20220264896Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Campylobacter species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Campylobacter species in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).Type: ApplicationFiled: December 21, 2021Publication date: August 25, 2022Inventor: Alexander SULAKVELIDZE
-
Patent number: 10711252Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Shigella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Shigella species in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).Type: GrantFiled: January 21, 2016Date of Patent: July 14, 2020Assignee: INTRALYTIX, INC.Inventors: Gary Pasternack, Alexander Sulakvelidze
-
Patent number: 9404089Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage.Type: GrantFiled: September 2, 2014Date of Patent: August 2, 2016Assignees: Zoctis Services LLC, Intrlytix Inc.Inventors: Jeremy Mathers, Alexander Sulakvelidze
-
Publication number: 20160215273Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Shigella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Shigella species in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).Type: ApplicationFiled: January 21, 2016Publication date: July 28, 2016Inventors: Gary PASTERNACK, Alexander SULAKVELIDZE
-
Patent number: 9320795Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of Clostridium species strains, in particular C. perfringens, C. septicum and C. difficile. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage. The invention also relates to the use of purified bacteriophage preparation in combination with antibiotics for the treatment of animals including poultry. The invention also relates to the use of the purified bacteriophage preparations as treatments effective against antibiotic-resistant strains of Clostridium.Type: GrantFiled: March 1, 2010Date of Patent: April 26, 2016Assignees: Zoctis Server LLC, Intrlytix IncInventors: Jeremy Mathers, Alexander Sulakvelidze
-
Patent number: 8956628Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five C. perfringens strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage.Type: GrantFiled: December 15, 2008Date of Patent: February 17, 2015Assignee: Zoetis Products LLCInventors: Jeremy J. Mathers, Alexander Sulakvelidze
-
Publication number: 20150044175Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage.Type: ApplicationFiled: September 2, 2014Publication date: February 12, 2015Inventors: Jeremy Mathers, Alexander Sulakvelidze
-
Patent number: 8685696Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Salmonella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Salmonella species in various settings (e.g., food safety, sanitation, probiotics).Type: GrantFiled: June 13, 2012Date of Patent: April 1, 2014Assignee: Intralytix, Inc.Inventors: Gary Pasternack, Alexander Sulakvelidze
-
Publication number: 20130336932Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Salmonella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Salmonella species in various settings (e.g., food safety, sanitation, probiotics).Type: ApplicationFiled: June 13, 2012Publication date: December 19, 2013Applicant: Intralytix, Inc.Inventors: Gary PASTERNACK, Alexander SULAKVELIDZE
-
Publication number: 20130164374Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: February 21, 2013Publication date: June 27, 2013Applicant: Intralytix, Inc.Inventors: J. Glenn MORRIS, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20120148505Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: August 22, 2011Publication date: June 14, 2012Applicant: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Patent number: 8003323Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: GrantFiled: November 4, 2008Date of Patent: August 23, 2011Assignee: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20100297086Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of Clostridium species strains, in particular C. perfringens, C. septicum and C. difficile. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five Clostridium species strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage. The invention also relates to the use of purified bacteriophage preparation in combination with antibiotics for the treatment of animals including poultry. The invention also relates to the use of the purified bacteriophage preparations as treatments effective against antibiotic-resistant strains of Clostridium.Type: ApplicationFiled: March 1, 2010Publication date: November 25, 2010Inventors: Jeremy Mathers, Alexander Sulakvelidze
-
Patent number: 7745194Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Staphylococcus aureus, in particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Staphylococcus aureus in various settings.Type: GrantFiled: September 16, 2008Date of Patent: June 29, 2010Assignee: Intralytix, Inc.Inventors: Gary R. Pasternack, Alexander Sulakvelidze
-
Publication number: 20100075398Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five C. perfringens strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage.Type: ApplicationFiled: December 15, 2008Publication date: March 25, 2010Applicants: ALPHARMA, INC., INTRALYTIX, INC.Inventors: Jeremy J. Mathers, Alexander Sulakvelidze
-
Publication number: 20100068787Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Staphylococcus aureus, in particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Staphylococcus aureus in various settings.Type: ApplicationFiled: September 16, 2008Publication date: March 18, 2010Applicant: Intralytix, Inc.Inventors: Gary Pasternack, Alexander Sulakvelidze
-
Patent number: 7674467Abstract: The present invention is directed to isolated Salmonella bacteriophage, and methods of using Salmonella bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Salmonella. The present invention also contemplates the use of Salmonella bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Salmonella.Type: GrantFiled: September 3, 2004Date of Patent: March 9, 2010Assignee: Intralytix, Inc.Inventors: Alexander Sulakvelidze, Shanmuga Sozhamamnnan, Gary R. Pasternack
-
Patent number: 7635584Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli O157:H7 in various settings.Type: GrantFiled: May 31, 2007Date of Patent: December 22, 2009Assignee: Intralytix, Inc.Inventors: Alexander Sulakvelidze, Gary R. Pasternack
-
Publication number: 20090297561Abstract: The invention provides methods of generating phage lysate bacterins, as well as phage lysate bacterin compositions. The invention further encompasses methods of vaccination comprising administering phage lysate bacterin to an animal in need thereof. The invention further encompasses methods of reducing infection or colonization of poultry or poultry eggs using phage bacterin lysates. Method of vaccination comprising administering to an animal in need of immunization an amount of phage lysate bacterin to induce an immune response.Type: ApplicationFiled: September 3, 2004Publication date: December 3, 2009Applicant: IntralytixInventors: Gary R. Pasternack, Alexander Sulakvelidze, Torrey Brown